Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-54175446 pharmacodynamics in healthy subjects
NCT02933762Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2016
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of JNJ-54175446 in Alzheimer's disease (AD) (13 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Levels of Aβ Fragments in Plasma at Day 8, Levels of Aβ Fragments in Cerebrospinal Fluid at Day 8 and 10 more. Started Sep 2016; status: completed.
02
Drugs
JNJ-54175446
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02933762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02933762.